Drug Trial Radar · NCT03393975
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Oct 13, 2017
Primary completion
Dec 28, 2023
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Baxalta now part of ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Jan 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed underneath the skin forming purple bruises or purpura, or from the surface of the skin. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them leading to lower than normal number of red blood cells. A lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in blood clotting, causes TTP. The enzyme breaks up another blood protein called von Willebrand factor that clumps together with platelets to form blood clots. Some people are born with this condition, others get the condition during their life. Many people who born with TTP experience frequent flareups that need to be treated right away. If not treated It can be fatal or cause lasting damage, such as brain damage or a stroke. BAX 930 is a medicine that replaces ADAMTS13 and can prevent or control TTP flareups, called TTP events. The main aim of this study is to compare the number of TTP events in people born with severe TTP when they treated with BAX 930 versus when they are treated with the standard treatment. Treatment will be given in 2 ways: * BAX 930 or standard treatment given to prevent TTP events from happening. * BAX 930 or standard treatment given to control an acute TTP event when it happens, according to the clinic's standard practice. Both BAX 930 and standard treatment are given slowly through a vein (infusion). At the first visit, the study doctor will check if you can participate in the study. If you are eligible and enter the study, you will follow an assigned schedule and either start with BAX 930 (Period 1) and then switch to standard treatment (Period 2) or start with standard treatment (Period 1) and then switch to BAX 930 (Period 2). Everyone will be treated with BAX 930 again for Period 3. Each Period will last approximately 6 months. If you enter the study to control an acute TTP event, you will follow a schedule receiving either BAX 930 or standard care to treat your acute TTP event. Once the acute TTP event has gotten better, you can decide to continue in the study and be given treatment to prevent TTP events from happening, following the schedule above. Another study's aim is to assess side effects from treatment with BAX 930 and standard treatment. To do that, the study doctor will ask you questions about your health at each study visit. The study doctors will also check how long BAX 930 stays in the blood of the participants, over time. They will do this from blood samples taken after participants receive their specific infusions of BAX 930. This will happen at different times during the study. 1 month after all treatment has been completed, participants will visit the clinic for a final check-up.
Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755Biological
Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg TAK-755 ORT during Period 1 and Period 2 and switch to TAK-755 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of TAK-755.
Standard of careBiological
Participants will receive Investigator-recommended Standard of care (SoC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic TreatmentTime frame: Up to 74.5 months
Locations
33 sites in 9 countries. Site status is shown where the registry gives one.
Winship Cancer Institute
Atlanta, Georgia
Alliance for Childhood Diseases, Cure 4 the Kids Foundation
Las Vegas, Nevada
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Ohio State Univ College Of Medicine
Columbus, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
The Methodist Hospital
Houston, Texas
AKH - Medizinische Universität Wien
Vienna, Austria
Hôpital Robert Debré - Paris
Paris, France
Hopital Claude Huriez - CHU Lille
Lille, Nord, France
Hôpital Necker - Enfants Malades
Paris, Paris, France
Hôpital Saint-Antoine
Paris, Paris, France
CHU Saint Etienne - Hôpital Nord
Saint-Priest-en-Jarez Cedex, Pays de la Loire Region, France
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Jena
Jena, Thuringia, Germany
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Italy
Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio Ferrarotto Alessi)
Catania, Italy
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Dipartimento di Medicina Traslazionale e di Precisione - "Sapienza" Universita di Roma
Rome, Italy
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Hyogo College of Medicine Hospital
Nishinomiya-shi, Hyōgo, Japan
Medical Hospital, Tokyo Medical and Dental University
Bunkyō City, Tokyo-To, Japan
Samodzielny Publiczny Dzieciecy Szpital Kliniczny
Warsaw, Poland
Instytut Hematologii i Transfuzjologii
Warsaw, Poland
Hospital General Universitario de Alicante
Alicante, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain
Hospital de Cruces
Barakaldo, Vizcaya, Spain
Royal Manchester Children's Hospital
Manchester, United Kingdom
University College London Hospitals
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.